Article Text

Download PDFPDF
The new GP contract: an opportunity for drugs and therapeutics
  1. James Cave, Editor-in-chief
  1. The Downland Practice, Berkshire, UK
  1. Correspondence to Dr James Cave, The Downland Practice, Berkshire, UK; jcave{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Details of the latest General Medical Services contract for general practitioners (GPs) in England were released on 31 January with implementation due to take effect from April 2019.1 At a time when general practice is struggling to cope with higher, more complex demands and a diminishing workforce, it is seen as a last chance to redevelop GP services in England and to do things differently.2 Broadly speaking, the 5-year framework includes a large injection of funding for primary care with much of it contingent on participation in primary care networks (PCNs).3 The development of PCNs unlocks money for additional staff including, in the first year, clinical pharmacists and social …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.